Several analysts have recently updated their ratings and price targets for Bicycle Therapeutics (NASDAQ: BCYC): 9/12/2023 – Bicycle Therapeutics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $44.00 price target on the stock. 9/12/2023 – Bicycle Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company […]
Shares of Bicycle Therapeutics plc (BCYC) are up 9% on Monday after the company announced that it will proceed with its plan to expedite the development of BT8009 for metastatic bladder cancer.
Histogen (NASDAQ:HSTO – Get Rating) and Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations. Risk & Volatility Histogen has a beta of 1.33, suggesting […]
Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Rating) have received an average rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average […]